-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2370 The Impact of Social Determinants and Diagnostic Inequities in Hodgkin Lymphoma Outcomes: A Comparative Analysis of South America and the United States

Program: Oral and Poster Abstracts
Session: 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Hematology Disease Topics & Pathways:
Hodgkin lymphoma, Adult, Clinical Practice (Health Services and Quality), Lymphomas, Diseases, Lymphoid Malignancies, Young adult , Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Ana Milena Cantillo Garcia Jr., MD1*, German R. Stemmelin Sr., MD2*, Sofía Gabriela Rivarola, MD2*, Maria Elvira Enciso Arrua, MD3*, Seisha Von Glasenapp, PhD4*, Fernando Warley, MSc, MD5*, Maria Orlova, MD6*, Rosa Oliday Rios Jiménez7*, Jule F Vasquez, MD8, Alfredo Quiroz, MD3*, Marialejandra Torres Viera, MD9*, Denisse Castro, MD10, Victoria Irigoin, MD11*, Brady E Beltran, MD12,13*, Henry Quintero, MD14,15*, Julio Dámaso Fernández-Águila, MD16*, Ana Carolina Oliver, MD17, Jorge J. Castillo, MD18, Luis Mario Villela, MD19*, Diego Fernando Garcez Paz20*, Bryan Valcarcel, MD, MPH21 and Luis Malpica, MD22*

1Hospital Britanico, Buenos Aires, BA, Argentina
2Hospital Británico, Buenos Aires, Argentina
3Departamento de Hematología, Hospital Central Instituto de Previsión Social, Asunción, Paraguay
4Departamento de Hematología, Hospital Central Instituto de Previsión Social, Asuncion, Paraguay
5Italian Hospital, Buenos Aires, Argentina
6Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
7Hospital Clínico Quirúrgico Hermanos Amejeiras, La Habana, Cuba
8Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
9Unidad Linfomas, Instituto Hematología y Oncología Universidad Central Venezuela, Caracas, Venezuela (Bolivarian Republic of)
10Hospital Edgardo Rebagliati Martins, Lima, Peru
11Hospital de Clinicas, Montevideo, Uruguay
12Instituto de Investigación en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Peru
13Servicio Oncología Médica, Hospital Edgardo Rebagliati, Lima, Peru
14Asociación Colombiana de Hematología y Oncología (ACHO), Bogotá, Colombia
15Clinica la Estancia, Popayan, Colombia
16Gustavo Aldereguía University Hospital, Cienfuegos, CUB
17Hospital Britanico de Uruguay, Montevideo, Uruguay
18Dana-Farber Cancer Institute, Bing Center for Waldenström Macroglobulinemia, Boston, MA
19Mexico, Mexico City, Mexico
20Instituto Nacional de Oncologia Ospedale INOOS, Ibague, Colombia
21Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Houston, TX
22Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

INTRODUCTION

Hodgkin lymphoma (HL) is a highly curable disease, with survival rates exceeding 90% in Western countries among predominantly White populations. However, clinical features and outcomes in other regions, such as South America, remain underexplored, particularly regarding the role of social determinants of health (SDOH). Understanding differences in outcomes across world regions is essential to improve outcomes globally. We conducted an exploratory international pooled analysis comparing HL subtypes and outcomes of patients with HL in South America with those in the United States (US).

METHODS

We designed a retrospective cohort study among patients aged ≥16 with newly diagnosed classical HL during 2010-2020. Patients with nodular lymphocytic HL were excluded. Data were obtained from the hospital-based registry of the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) across 6 South American countries and the US population-based registry of the Surveillance, Epidemiology, and End Results (SEER) program. Follow-up was available through 2023 for GELL and 2021 for SEER. Patients were stratified into South American, US Hispanic, and US White groups.

Primary endpoint was overall survival (OS), defined from diagnosis to death from any cause, and estimated only among patients who received chemotherapy with or without radiotherapy. Recurrence or progression data were not available from SEER. SDOH factors evaluated were insurance status (public vs. private) and PET scan availability at the end of treatment (EOT). PET-scan availability was assessed through a landmark analysis, assuming US patients generally performed EOT PET scans as standard of care. Time-to-event endpoints were analyzed using Kaplan-Meier and multivariable Cox regression methods.

RESULTS

We enrolled 818 South American, 3,663 US Hispanic, and 11,830 US White patients. In the entire cohort, the median age at diagnosis was 38 years (range 16-91) with a male predominance (54%). Compared to US Hispanic and US White patients, South American patients had a higher frequency of mixed cellularity HL (26% vs. 19% vs. 14%; p<0.001) and were diagnosed more frequently at stage III-IV disease (55% vs. 50% vs. 43%; p<0.001). The proportion of classical HL not otherwise specified was lower in the South American cohort (12% vs 32-36%). Age (range 36-39 years) and male predominance (54% for all) were similar across groups. Chemotherapy with or without radiotherapy was administered to 95% of South American patients, 84% of US Hispanic patients, and 87% of US White patients. The most common chemotherapy regimen in South America was ABVD (96%). Chemotherapy approaches were not available in SEER.

With a median follow-up of 63 months among all patients that received first-line treatment with curative intent, South American patients experienced a similar OS compared to US White patients (5-year OS 86% vs. 88%; Hazard ratio [HR]=1.25, 95% confidence interval [CI]=0.98-1.60). However, US Hispanic patients had relatively worse outcomes than US White patients (5-year OS 86% vs. 88%; HR=1.44, 95% CI=1.27-1.63). Subgroup analyses of OS outcomes across demographic, HL subtypes, and cancer stage groups remained similar. In a landmark analysis, South American patients who received EOT PET-scan had comparable OS to US White patients (HR=1.40, 95% CI=0.98-1.99), but those without access to PET-scan had significantly worse outcomes (HR=2.11, 95% CI=1.49-2.98). Insurance status did not affect OS.

CONCLUSION

This study improves our understanding of the epidemiology, management, and impact of SDOH in an underrepresented region, and findings should be validated with other hospital-based or cancer registries. The higher frequency of mixed cellularity HL in South American patients provides an opportunity to investigate the role of environmental factors, such as oncoviruses (e.g., EBV or HIV), in disease etiology. The lack of EOT PET scans highlights the need to improve access to standard procedures and explore alternative methods to assess treatment responses. The comparable survival outcomes to US data underscore the importance of expanding our cohort follow-up and data collection strategies to understand better the long-term risk of treatments and the impact of SDOH on survivorship outcomes in different regions. Addressing these unmet needs is essential for improving the outcomes of patients with HL globally.

Disclosures: Oliver: Abbvie: Consultancy; Servier: Consultancy; Roche: Consultancy. Castillo: Mustang Bio: Consultancy; BeiGene: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Kite Pharmaceuticals: Consultancy; Cellectar Biosciences: Consultancy, Research Funding; Janssen: Consultancy; LOXO: Consultancy, Research Funding. Malpica: Eisai: Research Funding; Dizal: Research Funding.

*signifies non-member of ASH